The Vanguard Group 13D and 13G filings for Heron Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-30 2:20 pm Purchase | 2025-12-31 | 13G | Heron Therapeutics, Inc. HRTX | The Vanguard Group | 9,820,384 5.350% | 1,360,600 (+16.08%) | Filing |
| 2025-10-30 3:16 pm Purchase | 2025-09-30 | 13G | Heron Therapeutics, Inc. HRTX | The Vanguard Group | 8,459,784 4.610% | 120,872 (+1.45%) | Filing |
| 2024-02-13 5:06 pm Purchase | 2023-12-29 | 13G | Heron Therapeutics, Inc. HRTX | The Vanguard Group | 8,338,912 5.560% | 532,627 (+6.82%) | Filing |
| 2023-02-09 11:22 am Sale | 2022-12-30 | 13G | Heron Therapeutics, Inc. HRTX | The Vanguard Group | 7,806,285 6.570% | -1,802,760 (-18.76%) | Filing |
| 2022-02-10 08:17 am Purchase | 2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX | The Vanguard Group | 9,609,045 9.430% | 1,297,277 (+15.61%) | Filing |
| 2021-02-10 10:57 am Purchase | 2020-12-31 | 13G | Heron Therapeutics, Inc. HRTX | The Vanguard Group | 8,311,768 9.150% | 455,202 (+5.79%) | Filing |